Due to the known expression of EGFR in colorectal cancer, a phase II trial of cetuximab, an anti-EGFR monoclonal antibody, in patients with refractory EGFR-positive (assessed by immunohistochemistry) colorectal cancer was undertaken [10]. This evidence concerns the gene EGFR and colorectal cancer.